Search
Relay Therapeutics Inc
RLAYAdd to Watchlist
18.650USD
+0.890+5.01%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
3.24BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-02The current earnings forecast score of Relay Therapeutics Inc is 8.92, ranking 34 out of 387 in the Biotechnology & Medical Research industry. The average price target is 14.50, with a high of 19.00 and a low of 6.00.
Analyst Rating
Based on
12
analysts
Buy
Current Rating
24.818
Target Price
+39.74%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
562
Total
5
Median
6
Average
Company name
Ratings
Analysts
Relay Therapeutics Inc
RLAY
12
CRISPR Therapeutics AG
CRSP
27
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
113
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Relay Therapeutics Inc's expected revenue for the next quarter?
Relay Therapeutics Inc's expected revenue is 660.00K.
What is Relay Therapeutics Inc's price target?
Analysts forecast that Relay Therapeutics Inc's price target is USD 14.50, with the highest forecast at USD 19.00 and the lowest forecast at USD 6.00.
How have Relay Therapeutics IncRLAY's recent earnings per share performed?
The market expectation was USD -0.41, while Relay Therapeutics IncRLAY's earnings per share (EPS) for the previous quarter was USD -0.32. EPS for the next quarter is expected at USD -0.39.
What is the analyst rating for Relay Therapeutics Inc?
Based on the ratings of Relay Therapeutics Inc's stock from 12 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.